Nykode Therapeutics AS (OSL:NYKD)

Market Cap	561.66M
Revenue (ttm)	87.09M
Net Income (ttm)	-266.37M
Shares Out	326.55M
EPS (ttm)	-0.83
PE Ratio	n/a
Forward PE	n/a
Dividend	1.00 (58.07%)
Ex-Dividend Date	May 27, 2025

Volume	254,192
Average Volume	1,360,424
Open	1.715
Previous Close	1.722
Day's Range	1.700 - 1.737
52-Week Range	1.550 - 17.200
Beta	1.17
RSI	30.86
Earnings Date	May 28, 2025

About Nykode Therapeutics AS

Nykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer, autoimmune, and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of locally advanced and metastatic tumors; and VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer. The co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2006
• Employees: 136
• Stock Exchange: Oslo Børs
• Ticker Symbol: NYKD

Financial Performance

In 2024, Nykode Therapeutics AS's revenue was $9.16 million, a decrease of -31.26% compared to the previous year's $13.32 million. Losses were -$38.82 million, 10.4% more than in 2023.

Financial numbers in USD